TMO Stock Price Today (September 2026) — Thermo Fisher Scientific Inc. Analysis & Key Metrics 2026-09-03
Thermo Fisher Scientific Inc. (TMO) is trading at $618.43, up 1.63% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $631.42 (2.1% upside).
- Volatility remains elevated (21.99% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.50% YoY) alongside significant competitive pressures.
TMO Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Thermo Fisher Scientific Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $268.66B
P/E Ratio
Forward P/E: 22.43
Revenue Growth
Year over Year
Analyst Target
+2.1% upside potential
Key Investor Questions About TMO
What investors need to know before buying
Based on current market data, TMO presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 57.44)
- Fundamentals say: Caution warranted (high leverage concerns)
TMO's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for TMO investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $42.55B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, TMO stock traded between $435.27 and $647.00—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 21.99% annualized volatility and β=0.87, the stock exhibits moderate correlation to market moves—making TMO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
TMO Stock Could Gain Following the Launch of EMPAD G2 Detector
Thermo Fisher's EMPAD G2 detector enhances 4D STEM imaging speed, sensitivity and workflow integration, strengthening its Analytical Instruments portfolio.
Partners Group Private Equity Ltd (LSE:PEY) (Q2 2026) Earnings Call Highlights: Strong ...
Despite a challenging market, the company realized over 14% of NAV in distributions and advanced AI initiatives, while navigating a dip in portfolio performance.
Thermo Fisher Scientific (TMO) Unveils New Tools For Electron Microscopy And Isotope Analysis
Thermo Fisher Scientific (NYSE:TMO) introduces the EMPAD G2 detector for high speed, high dynamic range 4D scanning transmission electron microscopy. The company launches Orbitrap Isora and Isora Pro Mass Spectrometers that integrate molecular level isotope ratio analysis. The new instruments target research in material science, environmental studies, geoscience, bioscience, and food authenticity. Consider looking at other stocks developing tools and infrastructure that support advanced...
Is Thermo Fisher Scientific Stock Outperforming the Nasdaq?
Thermo Fisher Scientific has outperformed the Nasdaq over the past year, yet Wall Street analysts remain bullish on the stock, reflecting confidence that its strong growth trajectory has further room to run.
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Unpopular Stocks We Find Risky
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Eli Lilly Is Pulling Away From the Rest of Healthcare
Its growth profile stands well above major sector peers.
Is Avantor a Buy as Revival Progress Faces Persistent Margin Pressure?
AVTR's Revival Program is lifting VWR growth and BMP orders, but margin pressure and soft earnings keep the recovery selective despite a higher 2026 outlook.
Explore More Analysis for TMO
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. (TMO) is currently trading at $618.43. The RSI (14-day) is at 57.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $631.42 implies 2.1% upside from current levels. Volatility is moderate at 22.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Thermo Fisher Scientific Inc. (TMO): The trailing P/E ratio is 33.25, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 22.43, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.06, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 4.34. Price-to-Sales is 4.93. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering TMO, the consensus price target is $631.42. This represents a 2.1% upside from the current price of $618.43. The range spans from a low target of $520.00 to a high target of $750.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Thermo Fisher Scientific Inc. (TMO) pays a dividend with a current yield of approximately 30.00%. The annualized dividend rate is $1.80 per share. The payout ratio is 9.7%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-09-15T00:00:00.000Z.
Key risks for Thermo Fisher Scientific Inc. (TMO) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Thermo Fisher Scientific Inc.'s (TMO) current debt and financial health profile: Total debt stands at $42.55B. The debt-to-equity ratio is 80.58, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.55, indicating strong short-term liquidity. The quick ratio is 1.01. The company holds $4.06B in cash and equivalents. Free cash flow is positive at $6.24B, providing a cushion for debt servicing and shareholder returns.